Navigation Links
Patient Recruitment Begins in India for Phase 3 Diabetes Trial
Date:11/7/2008

BETHESDA, Md., Nov. 7 /PRNewswire-FirstCall/ -- Spherix Incorporated (Nasdaq: SPEX) reported that patient recruitment for its Phase 3 clinical trial of its potential type 2 diabetes drug, Naturlose(R), has begun in India. Expectations for India are to provide more than 300 patients spread across 35 sites for the pivotal Phase 3 trial. "Now that enrollment efforts are underway in India, we believe that the Phase 3 trial will be completed on schedule as reported during the May 2008 Annual Shareholders Meeting. This truly represents a tremendous amount of hard work, both internally and externally, to achieve regulatory approval and patient recruitment in such a short period of time," said Randy W. Brown, Chief of Operations. Global enrollment is scheduled for completion by the end of the first quarter 2009, and the trial is scheduled to be completed in 2010.

Spherix Incorporated also announced the signing of a contract with Amarex, a Contract Research Organization (CRO) located in Germantown, MD, to oversee the work of two India CROs hired to execute the trial in India.

"It became quite clear that the trial was not executable solely in the United Sates with our known parameters; therefore, India became an obvious, viable solution. I now expect our ultimate deliverable, a new drug application, to be back on schedule," said Mr. Brown.

Certain statements contained herein are "forward looking" statements as defined in the Private Securities Litigation Reform Act of 1995. Because such statements include risks and uncertainties, actual results may differ materially from those expressed or implied. Factors that could cause actual results to differ materially from those expressed or implied include, but are not limited to, those
'/>"/>

SOURCE Spherix Incorporated
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Sunesis Pharmaceuticals Presents Clinical Trial Data of Voreloxin in Patients with Acute Myeloid Leukemia and Ovarian Cancer at the Chemotherapy Foundation Symposium
2. CuraGen Announces Preliminary Data from Ongoing Phase II Study Showing Clinical Activity of CR011-vcMMAE in Patients with Metastatic Melanoma
3. Boceprevir Phase II Study Showed High Rate of Sustained Response With 28- and 48-Week Regimens in Genotype 1 Treatment-Naive Hepatitis C Patients
4. New Study Shows that PEGASYS(R) Regimen Provides Higher Sustained Virological Response Rates for Hepatitis C Patients
5. Nebulized Perforomist(TM) Inhalation Solution Provided Prolonged Bronchodilation and Increased Patient Satisfaction Compared to Albuterol/Ipratropium MDI
6. Study Found That Long Term Use of Advair Diskus(R) 250/50 Did Not Adversely Affect Bone Loss in Patients with COPD
7. Study Results Show Epratuzumab Provided Clinically Meaningful Reduced Disease Activity in Patients With Lupus
8. Pivotal Phase III Data Confirm the Efficacy and Safety of Arpidas Intravenous Iclaprim in Treating Patients With Complicated Skin and Skin Structure Infections
9. Analysis of Long-Term Vicriviroc Data Provides Evidence of Sustained Viral Suppression, Increased CD4 Cell Counts and Tolerability in Treatment-Experienced HIV-Infected Patients
10. New Study Demonstrated ACTEMRA(R) (tocilizumab) Inhibited Progression of Joint Damage in Rheumatoid Arthritis Patients
11. ACTEMRA (R) (tocilizumab) Significantly Reduced Signs and Symptoms of Rheumatoid Arthritis in Patients Who Failed Prior Treatments
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2014)... Neurelis, Inc. ("Neurelis") today announced an agreement ... held by Biotie to purchase Neurelis, clearing the way ... diazepam) for pediatric and adult epilepsy patients who experience ... Biotie has advanced the development program for NRL-1 and ... work required for NDA submission to the FDA.  Given ...
(Date:7/10/2014)... July 10, 2014  Breg, Inc., a premier ... launched the FreeRunner™ knee brace with new innovations ... patella mal-tracking return to active lifestyles.  FreeRunner,s patent-pending ... braces, providing support when patients need it most, ... don,t. Patellofemoral issues are the most ...
(Date:7/10/2014)... , July 10, 2014  BC Technical, the ... MiE America , Inc., a leading provider of ... into a long-term agreement naming BC Technical as the ... MiE and BC Technical announced today ... to establish BC Technical as the service and systems ...
Breaking Medicine Technology:Neurelis Regains Rights to Intranasal Diazepam Program 2Neurelis Regains Rights to Intranasal Diazepam Program 3Breg Introduces Knee Brace to Help Runners with Patellofemoral Pain Syndrome 2BC Technical Partners With MiE America To Be Authorized Provider Of Systems & Service 2
... 20, 2011 Ann Arbor SPARK recently celebrated the conclusion ... and a reception.  At the Ann Arbor SPARK Boot Camp ... Boot Camp" winner, based on the quality of its investor ... engagement though the Ann Arbor SPARK Business Accelerator.   ...
... HYDERABAD, India, May 20, 2011 Neuland Laboratories Ltd., ... (APIs), complex intermediates, and contract research and manufacturing services ... results for the 2011 fiscal year (FY) ended March ... report that in fiscal year 2011, Neuland delivered on ...
Cached Medicine Technology:Brio Device Awarded Best of Ann Arbor SPARK's Boot Camp 2Neuland Labs Reports Financial Results for Fiscal Year 2011 2
(Date:7/13/2014)... 2014 A Xarelto lawsuit webpage ... to provide consumers with the most current information regarding ... the blood-thinning medication, as well as the growing ... around the country. The law firm is now offering ... from life-threatening internal bleeding and related complications while using ...
(Date:7/13/2014)... Hope Palliative & Hospice Care announced today that they ... Tamarack Senior Living Community in Palatine, IL. The group, called ... 3rd Wednesdays of every month. This group will begin ... at 55 S. Greeley St. Palatine, IL 60067. It ... cost for the group. , “A grief support group ...
(Date:7/13/2014)... Wa (PRWEB) July 13, 2014 According ... by Vkool.com, this is a comprehensive guide that features ... deal with KP (keratosis pilaris). This guide ... 1: What Is Keratosis Pilaris? ,     Chapter 2: ... I Know If I Have KP? ,     Chapter ...
(Date:7/12/2014)... Recently, Fadhits.com, a well-known wedding dress manufacturer and ... graduation dresses to its product line. In addition, the ... It wants to bring more benefits for its loyal fans. ... discounted prices, up to 72% off. , As a leader ... Its online shop is a good place for ladies who ...
(Date:7/12/2014)... The Passenger Information System market is ... $20,341.36 million by 2019, at an expected CAGR of ... The public transport infrastructure in North America is well ... almost every corner of the region. The growing ridership ... transport service providers are driving the North American Passenger ...
Breaking Medicine News(10 mins):Health News:Xeralto Lawsuit Page Launched By Wright & Schulte LLC To Provide Information On Potential For Xarelto Bleeding Side Effects, Growing Litigation 2Health News:Xeralto Lawsuit Page Launched By Wright & Schulte LLC To Provide Information On Potential For Xarelto Bleeding Side Effects, Growing Litigation 3Health News:Xeralto Lawsuit Page Launched By Wright & Schulte LLC To Provide Information On Potential For Xarelto Bleeding Side Effects, Growing Litigation 4Health News:Hope Hospice Announces Grief Support Group at the Tamarack Senior Living Community 2Health News:Living With KP Book Review Exposes Jennifer Richards' Keratosis Pilaris Guide – Vkool.com 2Health News:Living With KP Book Review Exposes Jennifer Richards' Keratosis Pilaris Guide – Vkool.com 3Health News:New Collection of Long Graduation Dresses Revealed by Fadhits.com 2Health News:North America Passenger Information System (ICT) Market worth $5,486.88 Million by 2019 - New Report by MicroMarket Monitor 2Health News:North America Passenger Information System (ICT) Market worth $5,486.88 Million by 2019 - New Report by MicroMarket Monitor 3Health News:North America Passenger Information System (ICT) Market worth $5,486.88 Million by 2019 - New Report by MicroMarket Monitor 4
... Yingxia,International, Inc. (OTC Bulletin Board: CYXI) ("China Yingxia" ... industry engaged in the,development, manufacture and distribution of ... in the People,s Republic,of China ("PRC"), today reported ... 31, 2008., First Quarter 2008 Highlights, ...
... goal of tailoring cancer treatment for each individual, researchers ... suggesting a simple blood test can help doctors more ... cancer. , It can take several weeks and sometimes ... working because it can take that long to observe ...
... protein called IGF-1R in patients with gastrointestinal stromal tumors ... responsive to the drug imatinib mesylate (known as Gleevec), ... the Fox Chase Cancer Center in Philadelphia. Preliminary ... might respond well to agents in development for treatment-resistant ...
... Digital Power,Corporation (Amex: DPW ) (herein "Digital Power") ... March 31, 2008., Digital Power reported revenue of ... of 15.6% from $2,742,000 for the same quarter,last year. ... of 2008 was,reported, compared to an operating profit of ...
... 15 /Xinhua-PRNewswire-FirstCall/ -- Genesis,Pharmaceuticals Enterprises, Inc. (OTC Bulletin ... company with its principal operations,in the People,s Republic ... quarter ended March 31, 2008, the Company,s third ... A 10QSB Form was filed for the quarter,with ...
... Alexza,Pharmaceuticals, Inc. (Nasdaq: ALXA ) announced today ... Vice President, Quality. He will have,responsibilities in the ... manufacturing operations and preclinical / clinical,product candidates. Mr. ... at Telik, Inc. in Palo Alto, California, where ...
Cached Medicine News:Health News:China Yingxia International, Inc. Reports First Quarter 2008 Results 2Health News:China Yingxia International, Inc. Reports First Quarter 2008 Results 3Health News:China Yingxia International, Inc. Reports First Quarter 2008 Results 4Health News:China Yingxia International, Inc. Reports First Quarter 2008 Results 5Health News:China Yingxia International, Inc. Reports First Quarter 2008 Results 6Health News:China Yingxia International, Inc. Reports First Quarter 2008 Results 7Health News:China Yingxia International, Inc. Reports First Quarter 2008 Results 8Health News:China Yingxia International, Inc. Reports First Quarter 2008 Results 9Health News:Study suggests blood test can help improve treatment outcomes for breast cancer patients 2Health News:Protein predicts Gleevec resistance in gastrointestinal tumors 2Health News:Digital Power Reports Financial Results for the First Quarter Ended March 31, 2008 2Health News:Digital Power Reports Financial Results for the First Quarter Ended March 31, 2008 3Health News:Genesis Pharmaceuticals Reports Results for the Third Quarter of Fiscal Year 2008 2Health News:Genesis Pharmaceuticals Reports Results for the Third Quarter of Fiscal Year 2008 3Health News:Genesis Pharmaceuticals Reports Results for the Third Quarter of Fiscal Year 2008 4Health News:Genesis Pharmaceuticals Reports Results for the Third Quarter of Fiscal Year 2008 5Health News:Genesis Pharmaceuticals Reports Results for the Third Quarter of Fiscal Year 2008 6Health News:Genesis Pharmaceuticals Reports Results for the Third Quarter of Fiscal Year 2008 7Health News:Genesis Pharmaceuticals Reports Results for the Third Quarter of Fiscal Year 2008 8Health News:Genesis Pharmaceuticals Reports Results for the Third Quarter of Fiscal Year 2008 9Health News:Genesis Pharmaceuticals Reports Results for the Third Quarter of Fiscal Year 2008 10Health News:Genesis Pharmaceuticals Reports Results for the Third Quarter of Fiscal Year 2008 11Health News:Genesis Pharmaceuticals Reports Results for the Third Quarter of Fiscal Year 2008 12Health News:Carlos A. Parra Joins Alexza Pharmaceuticals as Vice President, Quality 2
The Pach IV is the premier product for cornea thickness measurement in conjunction with Glaucoma screening....
Inquire...
... Immunosorbent Assays(ELISA) is intended for the detection ... Measles Rubeola) virus in human sera. Individual ... determination of immune status. Paired sera, acute ... or a significant rise in antibody as ...
Measles IgM ELISA test is an enzyme linked immunosorbent assay (ELISA) for the detection of IgG class antibodies to Measles (Rubeola) in human serum or plasma....
Medicine Products: